Vuno Inc.
Financials
Valuation Metrics
Vuno Inc.'s Market Cap is ₩956B. At end of 2025 it was ₩3129B. Ranked #1248 of 2,405 in KR market (top 52%), #677 of 1,627 on KOSDAQ (top 42%), #45 of 94 in Health Care Equipment & Services (top 48%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 95.63B KRW | KR#1,248/2,405 Sec#45/94 |
| Revenue | 30.22B KRW | KR#2,023/2,405 Sec#67/94 |
| Net Income | -11.05B KRW | KR—/2,405 Sec—/94 |
| Total Assets | 47.95B KRW | KR#2,219/2,405 Sec#75/94 |
| Net Assets | 35.69B KRW | KR#2,109/2,405 Sec#74/94 |
| Employees | 160 | KR#1,266/2,405 Sec#41/94 |
| Value | ||
| P/B | 2.68x | KR#2,099/2,405 Sec#74/94 |
| P/S | 3.16x | KR#2,020/2,405 Sec#66/94 |
| FCF Yield | -5.59% | KR—/2,405 Sec—/94 |
| Profitability | ||
| ROE | -30.96% | KR#2,181/2,405 Sec#79/94 |
| ROA | -23.04% | KR#2,258/2,405 Sec#81/94 |
| Op. Margin | -31.95% | KR#2,167/2,405 Sec#73/94 |
| Revenue Growth | -1.68% | KR#1,604/2,405 Sec#75/94 |
| Financial Health | ||
| Debt Ratio | 34.35% | KR#671/2,405 Sec#33/94 |
| Total Debt | 5.96B KRW | KR#1,747/2,405 Sec#61/94 |
| FCF | -5.35B KRW | KR#1,506/2,405 Sec#51/94 |
| Cash | 5.33B KRW | KR#1,972/2,405 Sec#67/94 |
| Current Ratio | 3.45x | KR#472/2,405 Sec#30/94 |
| Performance | ||
| 1Y Return | -71.66% | KR#2,304/2,405 Sec#92/94 |
| 1M Return | -18.20% | KR#1,773/2,405 Sec#72/94 |
| From 52W High | -75.91% | KR#2,207/2,405 Sec#88/94 |
| 1Y MDD | -84.46% | KR#2,339/2,405 Sec#91/94 |
| Trading | ||
| Volume | 111,646 shares | KR#588/2,405 Sec#21/94 |
| Trading Value | 747.1M KRW | KR#668/2,405 Sec#18/94 |
| Foreign Own. | 1.58% | KR#1,792/2,405 Sec#67/94 |
| Per Share | ||
| EPS | -789 KRW | KR—/2,405 Sec—/94 |
| BPS | 2,549 KRW | KR#1,955/2,405 Sec#62/94 |
Company Info
Vuno, an artificial intelligence medical enterprise founded in 2014, initiated its global business after launching South Korea's first AI medical device in 2018 and listing on KOSDAQ in 2021. The company uses deep learning to analyze medical data, offering diagnostic and predictive products for cardiac arrest risk, lesion detection, X-ray findings, and arrhythmia analysis. By developing its own AI engine, Vuno has reduced dependence on IT companies and is accelerating global market expansion, including securing FDA breakthrough device designation. It is headquartered in Seocho-gu, Seoul.